3′-Deoxy-3′-[18F]-Fluorothymidine PET Imaging Reflects PI3K-mTOR-Mediated Pro-Survival Response to Targeted Therapy in Colorectal Cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
3′-Deoxy-3′-[18F]-Fluorothymidine PET Imaging Reflects PI3K-mTOR-Mediated Pro-Survival Response to Targeted Therapy in Colorectal Cancer
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 9, Pages e108193
Publisher
Public Library of Science (PLoS)
Online
2014-09-24
DOI
10.1371/journal.pone.0108193
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 3'-Deoxy-3'-18F-Fluorothymidine PET Predicts Response to V600EBRAF-Targeted Therapy in Preclinical Models of Colorectal Cancer
- (2013) E. T. McKinley et al. JOURNAL OF NUCLEAR MEDICINE
- [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier’s disease
- (2012) Eliot T. McKinley et al. ANNALS OF NUCLEAR MEDICINE
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Rapid, microwave-assisted organic synthesis of selective V600EBRAF inhibitors for preclinical cancer research
- (2012) Jason R. Buck et al. TETRAHEDRON LETTERS
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
- (2011) J. Villanueva et al. CANCER RESEARCH
- [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells
- (2011) Cathy C. Zhang et al. CLINICAL CANCER RESEARCH
- [18F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment
- (2011) Dmitry Soloviev et al. EUROPEAN JOURNAL OF CANCER
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to BRAF Inhibition in Melanomas
- (2011) David B. Solit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
- (2009) C. Shah et al. CLINICAL CANCER RESEARCH
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer
- (2008) H. C. Manning et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway
- (2008) O Bermudez et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started